Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Recruiting now

Conditions studied: Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v6, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

In brief

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Key facts

Study ID

NCT04739072

Run by

M.D. Anderson Cancer Center

People needed

1000

Starts

2019-11-22

Expected to finish

2028-12-31

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Histological/cytological confirmation of colorectal adenocarcinoma.
• Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
• Ability to understand and the willingness to sign a written informed consent document.
• Willing to pursue standard of care surveillance post completion of curative therapies.
• Willing to provide blood samples for correlative research.

You may not qualify if…

• Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
• Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Baptist- MD Anderson Cancer Center — Jacksonville, Florida, United States
• The Queen's Medical Center — Honolulu, Hawaii, United States
• St. Luke's Cancer Institute — Boise, Idaho, United States
• Cooper Hospital UNIV MED CTR. — Camden, New Jersey, United States
• UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas, United States
• Houston Methodist Cancer Center — Houston, Texas, United States
• UT Health San Antonio MD Anderson Cancer Center — San Antonio, Texas, United States
• Banner - MD Anderson Cancer Center — Gilbert, Arizona, United States
• Baylor Scott & White Research Institute — Temple, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.